Scientists show that lecanemab clears amyloid plaques by engaging microglia through its Fc fragment, defining the cellular program behind its therapeutic effect Lecanemab, marketed as Leqembi, is a monoclonal antibody treatment for Alzheimer’s disease that reduces the buildup of toxic amyloid plaques in the brain and slows cognitive decline. Scientists from VIB and KU Leuven […]Health,Alzheimer’s Disease,Brain,Dementia,Microglia,Neurology,Neuroscience#Scientists #Uncover #Hidden #Mechanism #FDAApproved #Alzheimers #Drug1772298683
